Email Alert | RSS    帮助

中国防痨杂志 ›› 2020, Vol. 42 ›› Issue (4): 398-403.doi: 10.3969/j.issn.1000-6621.2020.04.018

• 综述 • 上一篇    下一篇

巨噬细胞的抗结核纳米递药系统的应用进展

向海滨,梁求真,李新霞,宋兴华()   

  1. 830054 乌鲁木齐,新疆医科大学第一附属医院骨科(向海滨、梁求真);新疆医科大学药学院(李新霞);暨南大学第一附属医院骨科(宋兴华)
  • 收稿日期:2019-12-10 出版日期:2020-04-10 发布日期:2020-04-07
  • 通信作者: 宋兴华 E-mail:songxinghua19@163.com
  • 基金资助:
    国家自然科学基金(81860394)

Advances in the application of anti-tuberculosis nanoscale drug delivery system targeting macrophages

XIANG Hai-bin,LIANG Qiu-zhen,LI Xin-xia,SONG Xing-hua()   

  1. *Department of Orthopedics, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
  • Received:2019-12-10 Online:2020-04-10 Published:2020-04-07
  • Contact: Xing-hua SONG E-mail:songxinghua19@163.com

摘要:

结核分枝杆菌作为一种巨噬细胞胞内寄生菌,传统药物治疗存在治疗周期长、生物利用度低、毒性大甚至耐药性增加等局限性问题。抗结核纳米递药系统作为一种抗结核新剂型,可将经济廉价的药物通过主动或被动方式递送到巨噬细胞内,以杀死正在复制或潜伏期的结核分枝杆菌。在此框架下,笔者探讨了抗结核纳米递药系统对巨噬细胞主被动靶向机制,及用于组装纳米递药系统的先进材料。此外,总结了影响靶向递送效率的因素及面临的挑战。

关键词: 结核, 巨噬细胞, 药物载体, 分子靶向治疗, 综述文献(主题), 纳米递药系统

Abstract:

Mycobacterium tuberculosis (MTB) is a facultative intracellular parasite of macrophages, traditional anti-TB therapy have limitations such as long course of treatment, low bio-availability, high systemic toxicity and even may induce drug resistance. As a new method of anti-tuberculous drug administration, the nanoscale drug delivery system can deliver low-cost drugs into macrophages actively or passively to inhibit the replicate or latent MTB. This review explores the active and passive targeting mechanism of anti-tuberculosis nanoscale drug delivery system to macrophages, and advanced materials for assembling nanoscale delivery system. In addition, factors affecting targeted delivery efficiency and challenges are summarized.

Key words: Tuberculosis, Macrophages, Drug carriers, Molecular targeted therapy, Review literature as topic, Nanoscale drug delivery system